An agreement between NHSE and Novartis Gene Therapies has been reached to enables families in England to have access to gene therapy for Spinal Muscular Atrophy.
- NHS England and Norvartis Gene Therapies have concluded an agreement that secures access for families in England to Zolgensma®▼ (onasemnogene abeparvovec), the gene therapy for spinal muscular atrophy (SMA).
- NICE issuing a draft guidance recommending onasemnogene abeparvovec as a treatment option on the NHS.
NHS England (NHSE) and Novartis Gene Therapies have concluded an agreement that enables access to Zolgensma® (onasemnogene abeparvovec) for use in the NHS in England for infants with a clinical diagnosis, or a genotype predictive, of spinal muscular atrophy (SMA) Type 1. Whilst the final terms, especially restrictions around use, are still to be finalised these are positive news for families with infants who have SMA type 1.
At TreatSMA we welcome the news and will continue to work with NHSE and Novartis Gene Therapies to ensure suitable access is established. However, we also understand that this announcement will not affect many of the existing patients across the country and therefore we continue to work along other avenues to ensure that ALL people with SMA can have access to suitable treatment.
More positive news for the SMA community! For or the full press release please from the company see Zolgensma NHSE announcement.
